<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-24T02:08:54Z</responseDate><request verb="GetRecord" identifier="oai:ruor.uottawa.ca:10393/24395" metadataPrefix="oai_dc">https://ruor.uottawa.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:ruor.uottawa.ca:10393/24395</identifier><datestamp>2024-02-23T09:14:29Z</datestamp><setSpec>com_10393_242</setSpec><setSpec>col_10393_11105</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Informed Decision Making for Patients with Advanced Pancreatic Cancer Considering Chemotherapy: Development and Evaluation of a Clinical Decision Aid for Patients</dc:title>
   <dc:creator>Gresham, Gillian</dc:creator>
   <dc:contributor>Wells, George</dc:contributor>
   <dc:subject>Advanced Pancreatic Cancer</dc:subject>
   <dc:subject>Chemotherapy</dc:subject>
   <dc:subject>Systematic Review</dc:subject>
   <dc:subject>Network meta-analysis</dc:subject>
   <dc:subject>Decision Aid</dc:subject>
   <dc:subject>Gemcitabine</dc:subject>
   <dc:subject>FOLFIRINOX</dc:subject>
   <dc:subject>Acceptability</dc:subject>
   <dc:subject>Feasibility</dc:subject>
   <dc:description>Pancreatic cancer is the fourth leading cause of cancer death in Canada. Significant advancements in chemotherapy for advanced pancreatic cancer have resulted in the need for a quantitative comparison between these treatments on a relative scale. Therefore, a systematic review and Bayesian network meta-analysis of randomized clinical trials was conducted using gemcitabine, the standard treatment, as the reference comparator. Based on results from the network meta-analysis, in which optimal treatments were identified and side effects of each treatment evaluated, an Internet-based patient decision aid was developed in order to present the benefits and risks of each therapy option: (1) Best supportive care (2) gemcitabine (3) FOLFIRINOX. The objective of the decision aid was to guide patients through the decision-making process based on their individual preferences and values.  The decision aid was deemed to be acceptable and feasible based on results from a pilot study conducted at The Ottawa Hospital Cancer Centre.</dc:description>
   <dc:date>2013-08-13T14:34:15Z</dc:date>
   <dc:date>2014-08-14T08:00:07Z</dc:date>
   <dc:date>2013</dc:date>
   <dc:date>2013</dc:date>
   <dc:type>Thesis</dc:type>
   <dc:identifier>http://hdl.handle.net/10393/24395</dc:identifier>
   <dc:identifier>http://dx.doi.org/10.20381/ruor-6694</dc:identifier>
   <dc:language>en</dc:language>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Université d&amp;apos;Ottawa / University of Ottawa</dc:publisher>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>